Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross p...
HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innov...
HONG KONG, Dec. 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innova...
HONG KONG, Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Viva Biotech Holdings Group (1873. H...
HONG KONG, Sept. 26, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological inno...
Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, repr...
HONG KONG, July 28, 2023 /PRNewswire/ -- In the face of ever-changing circumstances, technological ...
WATERTOWN, Mass., July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio ...
* DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-...
HONG KONG, June 2, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innova...
HONG KONG, May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China...
HONG KONG, April 12, 2023 /PRNewswire/ -- 6th-7th April, the "2022 SAPA-China Annual Conference - O...
HONG KONG, April 4, 2023 /PRNewswire/ -- Even with the ever-changing situation, technological innov...
Revenue and Gross Profit with Steady Growth Competitive Advantages of One-stop Platform Continuously...
JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here...
SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnova...
Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantages F...
SHANGHAI, China, July 27, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva Bio...